Publication: 2882

Publication: 2882

A randomized phase II study of anti-PD-1 antibody [MK-3475 (pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced Merkel cell carcinoma (Alliance A091605)

DOI

URL

Google Scholar

Citation:: J Clin Oncol vol 36 (15_suppl) TPS9599-TPS9599

Meeting Instance:: ASCO 2018
Year:: 2018
Type:: Abstract
Sub type:: Poster Discussion
Funding:: NCTN
Endpoint:: No-Endpoint
Analysis:: Trial-Description-Only
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Experimental
Sec. Committees:: Radiation Onc

Pharmas:: Merck
Grants:: U10CA180821, U10CA180882; U10CA180868, U10CA180888, U24CA196171

Corr. Author:
Authors:: Jason Luke Steven Chmura Joseph Salama Hania Al-Hallaq Charles Hsu Sue Yom Mark Kozloff Jacob Allred Pamela Munster Gary Schwartz

Networks:: CA824, COLUMBIA, LAPS-IL057, LAPS-MN026, LAPS-NC010, LAPS-PA015

Study: Alliance-A091605
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: